aCenter for Biostatistics in AIDS Research and the Department of Biostatistics, Harvard University, Boston, Massachusetts, USA
bDepartment of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
cLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA
dDuke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
ePublic Health Research Institute Center, New Jersey Medical School-Rutgers University, Newark, New Jersey, USA
fInstitute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany
gGerman Center for Infection Research (DZIF), Partner Site Bonn, Cologne, Germany
hDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
iDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
jIBIS Biosciences Inc., an Abbott Company, Carlsbad, California, USA
kDivision of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
lUniversity of California, San Francisco General Hospital, San Francisco, California, USA
mDepartments of Pharmacology, Molecular Biology and Microbiology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
Citation Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR, Manca C, Tran TTT, Domitrovic TN, Higgins PG, Seifert H, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Sampath R, Hall T, Marzan C, Fowler VG, Jr., Chambers HF, Bonomo RA, for the Antibacterial Resistance Leadership Group (ARLG). 2017. Correction for Evans et al., “Informing antibiotic treatment decisions: evaluating rapid molecular diagnostics to identify susceptibility and resistance to carbapenems against Acinetobacter spp. in PRIMERS III.” J Clin Microbiol 55:1970. https://doi.org/10.1128/JCM.00525-17.